CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.


The T α 1 peptide can be administered via subcutaneous injection or as a transdermal cream. T α 1 has been found to be very safe, and there have not been any documented side effects associated with its administration. It is approved in more than 37 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and various vaccines.
An intact hypothalamic-pituitary axis is required to achieve the maximal effect of GHSs on GH release. GHRH and somatostatin both influence the action of GHSs, augmenting and diminishing the magnitude of the GH pulse, respectively. When GHRH is administered in combination with GHSs, the effect is synergistic, the magnitude of the GH pulse being greater than that obtained from the sum of the two agents administered separately. GHS stimulation of GH secretion requires the presence of GHRH. In members of a family with a homozygous inactivating mutation of the GHRH receptor, hexarelin was ineffective in stimulating GH release. In addition, children who are GH-deficient as a result of pituitary stalk transsection are unresponsive to GHSs. Thus, somatotroph exposure to GHRH is necessary for GHSs to exert their action.
Perhaps, the primary reason why peptides are used in bodybuilding has to do with how they improve growth hormone production. It is no longer a secret how HGH helps to improve lean muscle mass. Your body uses peptides to promote increased secretion of HGH. They, therefore, make it easier for interested persons to achieve bigger muscle mass. Their usage may help enhance strength. It is even said that these small amino acid chains could boost testosterone production.
GHRH (1 μg/kg) plus GHRP-6 (1 μg/kg) is given intravenously at 0 minutes and blood drawn for GH sampling at 0 and 120 minutes [200]. GH releasing peptide-6 (GHRP-6) is an artificial hexapeptide [96] that activates the ghrelin receptor [98]. Combined administration of GHRP-6 and GHRH is the most potent stimulus to GH release, with excellent reproducibility and no serious side effects [96]. GHRH/GHRP-6 is a viable alternative to the ITT in patients with organic pituitary disease, however there is overlap between GH levels attained in the control group and severely GH-deficient patients. Since GHRH and GHRP act directly on the pituitary, it is possible that their administration restores GH secretion in patients with a deficiency of these secretagogues because of hypothalamic disease [201].
Lactating nipples: GHRP-6 side effects include that of increased Prolactin secretion, which can result in lactation from the nipples. This is, however, a rare occurrence but it can happen in sensitive individuals. GHRP-6 exhibits the ability to induce secretion of Cortisol and Prolactin[3], but studies have shown that the Prolactin and Cortisol increases in most test subjects were not altered at all at GHRP-6 doses of 100mcg or less[4] [5]. Doses above 100mcg are said to increase Prolactin secretion, though minimally, and at these minimal levels lactation should not present itself. However, some users have reported lactation which can be the result of a sensitive individual or the result of much higher doses of GHRP-6. Prolactin can be lowered through the use of a Prolactin antagonist such as Cabergoline, Pramipexole, Bromocriptine, and even vitamin B6.
However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce.
However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce.
ADV Research ADV-033 (Ligandrol LGD-4033 SARM Alternative) PRODUCT STRENGTH (CONCENTRATION): 30MG/ML KEY BENEFITS ADV-033 is the best-in-class for bulking Highly anabolic, with “Anabolics-like” results Excellent for re composition Fast recover Protects muscle and prevents wasting Promotes healing and repair Nontoxic, so it doesn’t harm the liver or prostate. Enhances strength, power, and performance GENDER SUITABILITY ADV-033 is suitable for use…

The two peptides CJC 1295 Ipamorelin, are often used in conjunction for better results. Known individually as CJC 1295 and Ipamorelin, these peptides have similar roles, which we will look at later. But for now, the CJC 1295 and Ipamorelin combination, is chiefly used together because the production of growth hormone secretion is 10 times more effective than using them individually. This makes it convenient for most users, to guarantee quicker results. Above all, it is popular among athletes, bodybuilders and weightlifters in need of building strength or speeding up the recovery of an injury.
Without going into great detail, think of GHRP’s as targeting a pulse when you want it; meaning, once you take it, you get a burst of GH. On the other hand, with GHRH’s you really have to time when your body will have its own pulse to get the most out of administering them. In simple terms, if you use GHRH's at the wrong time, the results are minimal.
Hexarelin is a peptide that is derived from GHRP 6, but has been optimized to enhance its metabolic stability. Like the other GHSs, hexarelin increases hGH production, resulting in increased muscle mass, bone density, skin elasticity, and decreased body fat. Unlike the other GHRPs, however, hexarelin does not lead to a substantial increase in ghrelin and therefore does not cause the same appetite stimulation. This peptide has been further promoted for its cardioprotective and regenerative action as well. Hexarelin would be an ideal choice for those looking to benefit from increased growth hormone without appetite stimulation.
CJC-1295 is a fast-acting Growth Hormone Releasing Hormone designed to enhance the body’s natural production and release of human growth hormone and Insulin-like Growth Factor 1 (IGF-1). In doing so, CJC-1295 reverses the age-related decline, generates new muscle cells and increases fat loss. Another great trait of CJC-1295 is its ability to promote slow wave sleep, a deep sleep responsible for the highest levels of cell regeneration, muscle growth and memory retention.
The T α 1 peptide can be administered via subcutaneous injection or as a transdermal cream. T α 1 has been found to be very safe, and there have not been any documented side effects associated with its administration. It is approved in more than 37 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and various vaccines.
Growth Hormone Releasing Peptides (GHRP) are a class of compounds, which stimulate the release of growth hormone. GHRP variants include GHRP-2, GHRP-6, hexarelin, ipamorelin (Thomas et al, 2011) and agents with similar actions including CJC-1295 (Teichman et al, 2006, Acherman et al, 1999, Walker et al, 2006). These agents are considered peptide hormones. GHRPs are thought to act by stimulating the release of endogenous human growth hormone leading to pharmacological effects such as increased bone mineral density, increased lean muscle mass, modest improvements in strength and improved recovery from injuries such as fractures (Smith, 2005).
ADV Research ADV-11 (YK-11 SARM Alternative) All orders will be dispatched on Friday June 15th. KEY BENEFITS Powerful experimental myostatin inhibitor Potentially promotes lean muscle growth and increase lean body mass Potentially helps build on your genetic potential Potentially stimulates hair regrowth Potentially no negative impact on prostate size GENDER SUITABILITY ADV-11 may be suitable for use by both males…
An intact hypothalamic-pituitary axis is required to achieve the maximal effect of GHSs on GH release. GHRH and somatostatin both influence the action of GHSs, augmenting and diminishing the magnitude of the GH pulse, respectively. When GHRH is administered in combination with GHSs, the effect is synergistic, the magnitude of the GH pulse being greater than that obtained from the sum of the two agents administered separately. GHS stimulation of GH secretion requires the presence of GHRH. In members of a family with a homozygous inactivating mutation of the GHRH receptor, hexarelin was ineffective in stimulating GH release. In addition, children who are GH-deficient as a result of pituitary stalk transsection are unresponsive to GHSs. Thus, somatotroph exposure to GHRH is necessary for GHSs to exert their action.
Investigations reported that GHRP-6 is more efficient than GHRH itself in monkeys and performs synergistically when combined or applied together. An example of this combination would be GHRP-2 and CJC-1295. GHRP-6 is believed to be acting naturally on both pituitary and hypothalamic sites (Fairhall et al. 1995). In a time-dependent and dose-dependent manner, the primary pituitary cells of rats were demonstrated on. From the studies, the concentrations of the GHRP-6 needed for the half-maximal and maximal stimulation were 7 x 10(-9) and 10(-7) M, respectively.

In 1984, a synthetic hexapeptide, His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 (GHRP-6), was identified by Bowers and colleagues. This hexapeptide was shown to potently stimulate GH release in vitro and in vivo by an unknown mechanism. Because of its poor oral bioavailability (0.3%) and short half-life (20 min) in human serum, GHRP-6 was selected only as a structural model to design a nonpeptide mimetic. Based on the structure–activity relationships (SARs) of GHRP-6, the nonpeptidyl growth hormone secretagogue (GHS) L-692,429 was identified by Smith et al. in 1993. This nonpeptidyl GHS synergizes with GHRP-6 to stimulate GH release and cAMP production, accompanied by a significant increase in intracellular calcium concentration ([Ca2 +]i), indicating that this nonpeptidyl GHS acts through a distinct signal transduction pathway. In 1995, a potent oral GHS L-163,191 (MK-0677) was reported by Patchett et al. This agent was found to have excellent oral bioavailability and specificity in its release of GH, without significant effect on plasma levels of other hormones such as aldosterone, luteinizing hormone, thyroxine, and prolactin.
At the histological analysis, and from a qualitative perspective, these wounds appeared less inflamed and with a higher degree of ECM organization, given by far less fibrin accumulation and thinner and horizontally distributed collagen bundles. Vessels were also aligned with the collagen fibers. Thus, the treatment not only reduced the wound area but also appeared to be associated with differences in the quality of the ECM as the inflammatory infiltrate. Figure 2(a) is representative of the GHRP-6 effect on the inflammatory response, illustrating the reduction of infiltrated cells as compared to placebo-treated wounds (Figure 2(b)).
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.
Results and expectations from an HGH secretagogue such as GHRP-6 should be all of the same effects that any other form of Human Growth Hormone would provide. This includes fat loss, muscle mass increases, strength gains, healing and repair of joints and connective tissue, and a plethora of other benefits and changes. An important note to make is that the effects from any HGH application, whether it be an endogenous release from a GHRH or synthetic HGH administration, will all occur rather steadily over a longer period of use. Dramatic results within weeks are never to be expected, but with proper nutrition and training, dramatic performance and physique changes should occur steadily over the course of several months of application. For more information on HGH specific results and expectations, please see the Human Growth Hormone profile.

The conclusion comes down to which peptides should you use. This is going to depend on personal use and experience. Whether you are into bodybuilding, gaining an edge in sports or just looking for health and wellness and anti aging properties, peptides offer a little something for everyone. There are many peptides that are not covered below, but as an introduction into the peptide world these are the most generic and widely used. As with any supplement or drug, please do your own research before diving into using peptides.


GHRP-6 is normally always manufactured as lyophilized (freeze-dried) powder contained in vials in amounts of 5mg. Some companies might manufacture amounts greater or lesser than 5mg per vial, but the standard is generally 5mg/vial. The lyophilized powder contained within the vial will need to be reconstituted with bacteriostatic water in order for it to be injected. After reconstitution, the solution must then be refrigerated in storage. If left in hot environments or in room temperature environments for extended periods of time, the protein structure will degrade and become ineffective. For reconstitution, users will typically mix 3ml of bacteriostatic water with the powder gently. However, users can and do frequently reconstitute the powder with less (or more) water which will yield different concentrations of GHRP-6. For example, reconstitution of 5mg of powder with 3ml of water will yield GHRP-6 doses of 166mcg per 0.1ml (or 10iu on an insulin syringe).

From the information above we can determine that GHRP-6 is a drug which has some great benefits for the human body. It has in a very short period of time grabbed the attention of athletes and body builders around the world for its all in one utility. Not only is this drugged being used for cutting cycles, it is also being pursued as a stamina booster, muscle booster and a protective agent against weakening of the bones.
to amend the Standard for the Uniform Scheduling of Medicines and Poisons to include vitamin D, as a single weekly dose of up to 175 micrograms (7000IU) per recommended dose, in Schedule 3 (noting that the wording "per recommended weekly dose" in the interim decision's proposed Schedule 3 entry should have read "per recommended single weekly dose"); and
There’s no question this is a slightly safer version than GH, but it’s got plenty of athletes in hot H2O for testing the waters. Famously, this is the peptide the Essendon footballers were caught out using which led to the government shutting down regulatory loopholes used to legally get it into Australia. So assess all your risks before you take it then be honest with a doctor if you are considering it, particularly if you want to heal an injury, because your health is far more valuable than any improvements to your reflection.
×